Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceuticals Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany.
Center for Radioisotope and Radiopharmaceutical Technology, National Nuclear and Energy Agency (BATAN), Puspiptek Area, Serpong, South Tangerang, Indonesia.
Molecules. 2019 Jul 31;24(15):2791. doi: 10.3390/molecules24152791.
Phosphodiesterase 2A (PDE2A) is highly expressed in distinct areas of the brain, which are known to be related to neuropsychiatric diseases. The development of suitable PDE2A tracers for Positron Emission Tomography (PET) would permit the imaging of the PDE2A and evaluation of disease-mediated alterations of its expression. A series of novel fluorinated PDE2A inhibitors on the basis of a Benzoimidazotriazine (BIT) scaffold was prepared leading to a prospective inhibitor for further development of a PDE2A PET imaging agent. BIT derivatives (-) were obtained by a seven-step synthesis route, and their inhibitory potency towards PDE2A and selectivity over other PDEs were evaluated. demonstrated much higher inhibition than other BIT derivatives (82.9% inhibition of PDE2A at 10 nM). displayed an IC for PDE2A of 3.33 nM with 16-fold selectivity over PDE10A. This finding revealed that a derivative bearing both a 2-fluoro-pyridin-4-yl and 2-chloro-5-methoxy-phenyl unit at the 8- and 1-position, respectively, appeared to be the most potent inhibitor. studies of using mouse liver microsomes (MLM) disclosed as a suitable ligand for F-labeling. Nevertheless, future metabolism studies are required.
磷酸二酯酶 2A(PDE2A)在大脑的特定区域高度表达,这些区域与神经精神疾病有关。开发合适的磷酸二酯酶 2A(PDE2A)正电子发射断层扫描(PET)示踪剂将允许对 PDE2A 进行成像,并评估其表达的疾病介导的改变。基于苯并咪唑并三嗪(BIT)支架的一系列新型氟化 PDE2A 抑制剂的制备导致了进一步开发 PDE2A PET 成像剂的潜在抑制剂。通过七步合成路线获得了 BIT 衍生物(-),并评估了它们对 PDE2A 的抑制活性和对其他 PDE 的选择性。与其他 BIT 衍生物相比,(-)表现出更高的抑制活性(在 10 nM 时对 PDE2A 的抑制率为 82.9%)。对 PDE2A 的 IC 为 3.33 nM,对 PDE10A 的选择性为 16 倍。这一发现表明,在 8-和 1-位分别带有 2-氟-吡啶-4-基和 2-氯-5-甲氧基-苯基单元的衍生物似乎是最有效的抑制剂。使用小鼠肝微粒体(MLM)进行的研究表明,(-)适合 F 标记。然而,需要进一步的代谢研究。